news
Insilico and Qilu partner to create generative AI cardiometabolic drugs
Insilico Medicine and Qilu Pharmaceutical Group are expanding their existing R&D collaboration to apply generative AI to cardiometabolic drug discovery.
List view / Grid view
Hit-to-Lead
news
Targeting cPLA2 enzyme may reduce brain inflammation in Alzheimer’s
Researchers have identified new drug candidates that selectively target the cPLA2 enzyme, a key driver of brain inflammation linked to Alzheimer’s disease, offering a potential new approach to reducing risk in people with the APOE4 gene.
article
Drug development in 2026: NAMs, safety and regulatory changes
2026 is set to be a pivotal year for drug discovery, with advances in NAMs and evolving regulatory approaches promising faster, safer early drug development and accelerated delivery of therapies for patients with rare or unmet medical needs.
article
Disrupting the biologics market through innovations in macrocycle R&D
New macrocycle technologies are turning a once difficult drug class into a scalable engine for developing potent oral therapies.
news
insitro expands AI drug discovery with CombinAbleAI acquisition
insitro has acquired Israeli AI therapeutics company CombinAbleAI and launched its TherML platform, creating an end-to-end, modality-agnostic system for designing small molecules, antibodies, oligonucleotides and other complex biologics.
news
New study revives long-doubted target for depression drugs
Researchers have shown that changing the molecular structure of NK1 receptor antagonists may restore antidepressant effects after decades of failed trials.
news
Schrödinger partners with Lilly TuneLab on AI drug discovery
Schrödinger has announced a collaboration with Eli Lilly’s TuneLab platform, integrating advanced AI-driven drug discovery workflows into its LiveDesign enterprise informatics system.
news
New Type 2 diabetes drugs may improve insulin sensitivity
Scientists have used advanced computer modelling and lab techniques to design potential new diabetes drugs that improve insulin sensitivity.
article
Peptides in practice: what it takes to advance these therapies to clinic
Peptide therapeutics are emerging as a powerful class of medicines capable of targeting diseases that challenge traditional modalities. This article reveals their rising clinical impact and the key development, safety and translational challenges that must be addressed to bring them successfully to patients.
article
The future of obesity drugs starts in preclinical discovery
Progress in preclinical models and biomarker science is improving early-stage obesity drug development. This article outlines the emerging targets and technologies behind this shift.
news
AI-powered CKD drug ISM4808 licensed for kidney disease therapy
Insilico Medicine has partnered with TaiGen Biotechnology to exclusively license its AI-designed PHD inhibitor, ISM4808, for the treatment of CKD-related anaemia in Greater China.
news
Blocking the P2X4 receptor: a potential pathway to new therapies
Researchers have discovered how to inhibit the P2X4 receptor, a key protein linked to chronic pain, inflammation and certain cancers.
whitepaper
Lab Automation: Where Discovery Scales
Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
article
When chemistry corrects biology: the deuterated return of a MET inhibitor
A promising MET inhibitor failed in the clinic due to human-specific metabolism. Now its deuterated analogue, DO-2, is showing that a simple isotope swap might overcome the problem.
news
New antibiotic discovery could help tackle antimicrobial resistance
Scientists have discovered a powerful new antibiotic hidden within the compound pre-methylenomycin C lactone, which shows real effectiveness against drug-resistant infections such as MRSA and VRE.
